• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤抗原刺激的转染白细胞介素-12 和白细胞介素-18 的树突状细胞对小鼠结肠癌细胞模型抗肿瘤反应生成的有益作用。

The Beneficial Effect of IL-12 and IL-18 Transduced Dendritic Cells Stimulated with Tumor Antigens on Generation of an Antitumor Response in a Mouse Colon Carcinoma Model.

机构信息

Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.

出版信息

J Immunol Res. 2022 Mar 25;2022:7508928. doi: 10.1155/2022/7508928. eCollection 2022.

DOI:10.1155/2022/7508928
PMID:35372586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8975686/
Abstract

The main purpose of our study was to determine the effect of dendritic cell (DC) transduction with lentiviral vectors carrying sequences of and/or genes on the level of antitumor activity and . We examined the ability of DCs to migrate to the tumor-draining lymph nodes and infiltrate tumor tissue and to activate the local and systemic antitumor response. On the 15th day, DCs genetically modified for production of IL-12 and/or IL-18 were administered peritumorally to C57BL/6 female mice with established MC38 tumors. Lymphoid organs and tumor tissue were collected from mice on the 3rd, 5th, and 7th days after a single administration of DCs for further analysis. Administration of DCs transduced for production of IL-12 alone and in combination with IL-18 increased the inflow and activity of CD4 and CD8 T lymphocytes in the tumor microenvironment and tumor-draining lymph nodes. We also found that even a single administration of such modified DCs could trigger a systemic antitumor response as well as inhibit tumor growth. Application of the developed DC-based vaccines may exert a favorable impact on stimulation of an antitumor immune response, especially if these DC vaccines are administered repeatedly.

摘要

我们研究的主要目的是确定转导树突状细胞（DC）的慢病毒载体携带和/或基因序列对肿瘤活性和的影响。我们研究了 DC 向肿瘤引流淋巴结迁移、浸润肿瘤组织以及激活局部和全身抗肿瘤反应的能力。在第 15 天，将产生 IL-12 和/或 IL-18 的基因修饰的 DC 瘤周给药于已建立 MC38 肿瘤的 C57BL/6 雌性小鼠。在单次给予 DC 后第 3、5 和 7 天，从小鼠中收集淋巴器官和肿瘤组织进行进一步分析。单独转导产生 IL-12 的 DC 以及与 IL-18 联合转导的 DC 的给药增加了肿瘤微环境和肿瘤引流淋巴结中 CD4 和 CD8 T 淋巴细胞的流入和活性。我们还发现，即使单次给予这种修饰的 DC 也可以引发全身性抗肿瘤反应并抑制肿瘤生长。基于 DC 的疫苗的应用可能对刺激抗肿瘤免疫反应产生有利影响，特别是如果这些 DC 疫苗反复给予。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/f02258e6a2e3/JIR2022-7508928.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/9b9124fcf8a6/JIR2022-7508928.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/3caf79ba44a1/JIR2022-7508928.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/7e2d527ef7a8/JIR2022-7508928.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/2aa233eddb09/JIR2022-7508928.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/de2df39e724c/JIR2022-7508928.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/3dde623f444d/JIR2022-7508928.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/dfe7aa1660ea/JIR2022-7508928.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/9597b5342dde/JIR2022-7508928.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/ca740b0f72d3/JIR2022-7508928.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/f02258e6a2e3/JIR2022-7508928.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/9b9124fcf8a6/JIR2022-7508928.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/3caf79ba44a1/JIR2022-7508928.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/7e2d527ef7a8/JIR2022-7508928.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/2aa233eddb09/JIR2022-7508928.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/de2df39e724c/JIR2022-7508928.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/3dde623f444d/JIR2022-7508928.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/dfe7aa1660ea/JIR2022-7508928.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/9597b5342dde/JIR2022-7508928.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/ca740b0f72d3/JIR2022-7508928.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830c/8975686/f02258e6a2e3/JIR2022-7508928.010.jpg

相似文献

1
The Beneficial Effect of IL-12 and IL-18 Transduced Dendritic Cells Stimulated with Tumor Antigens on Generation of an Antitumor Response in a Mouse Colon Carcinoma Model.肿瘤抗原刺激的转染白细胞介素-12 和白细胞介素-18 的树突状细胞对小鼠结肠癌细胞模型抗肿瘤反应生成的有益作用。
J Immunol Res. 2022 Mar 25;2022:7508928. doi: 10.1155/2022/7508928. eCollection 2022.
2
Combined therapy with methotrexate nanoconjugate and dendritic cells with downregulated IL-10R expression modulates the tumor microenvironment and enhances the systemic anti-tumor immune response in MC38 murine colon carcinoma.甲氨蝶呤纳米偶联物和下调 IL-10R 表达的树突状细胞联合治疗调节 MC38 结肠癌细胞肿瘤微环境并增强全身抗肿瘤免疫反应。
Front Immunol. 2023 Mar 23;14:1155377. doi: 10.3389/fimmu.2023.1155377. eCollection 2023.
3
Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.局部给予白细胞介素-12转染的树突状细胞可诱导小鼠肝脏对结肠腺癌产生抗肿瘤免疫反应。
J Exp Ther Oncol. 2002 Nov-Dec;2(6):337-49. doi: 10.1046/j.1359-4117.2002.01050.x.
4
Generation of antitumor response by IL-2-transduced JAWS II dendritic cells.白细胞介素 2 转导的 JAWS II 树突状细胞引发抗肿瘤反应。
Immunobiology. 2011 Oct;216(10):1074-84. doi: 10.1016/j.imbio.2011.05.006. Epub 2011 May 14.
5
Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response.作为抗肿瘤疫苗应用的负载肿瘤抗原的小鼠树突状细胞的组织定位及其对免疫反应的影响。
Folia Histochem Cytobiol. 2007;45(4):349-55.
6
Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.用鼠白细胞介素12基因转导的JAWS II小鼠树突状细胞产生抗肿瘤反应。
Oncol Rep. 2007 May;17(5):1249-57.
7
The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.细胞因子基因共转导对使用表达肿瘤相关抗原的基因修饰树突状细胞进行癌症疫苗治疗的增强作用。
Int J Oncol. 2006 Apr;28(4):947-53.
8
Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy.利用慢病毒载体编码针对 IL-10 的 shRNA 重新编程小鼠结肠癌微环境，作为基于树突状细胞的有效化疗免疫治疗的一部分。
J Exp Clin Cancer Res. 2018 Jun 28;37(1):126. doi: 10.1186/s13046-018-0799-y.
9
Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.同时表达黑色素瘤相关抗原和白细胞介素-12的小鼠树突状细胞的免疫学特性及疫苗效力
Cancer Gene Ther. 2005 Jan;12(1):72-83. doi: 10.1038/sj.cgt.7700772.
10
Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinoma.在多种基于树突状细胞的疫苗支持下，使用环磷酰胺进行治疗可诱导针对MC38结肠癌的CD4⁺ T细胞反应多样化。
Int J Oncol. 2016 Feb;48(2):493-505. doi: 10.3892/ijo.2015.3278. Epub 2015 Dec 7.

引用本文的文献

1
Natural carrier systems in cancer vaccines and immunotherapy.癌症疫苗和免疫疗法中的天然载体系统。
Hum Vaccin Immunother. 2025 Dec;21(1):2535787. doi: 10.1080/21645515.2025.2535787. Epub 2025 Jul 24.
2
Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development.慢病毒载体的应用进展：从基因治疗到疫苗开发
Mol Biotechnol. 2025 Jul 5. doi: 10.1007/s12033-025-01472-y.
3
Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Efficacy.基于树突状细胞的癌症疫苗：调节固有淋巴细胞对抗肿瘤疗效的影响

本文引用的文献

1
CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4.CD86 是一种选择性的 CD28 配体，可在 CTLA-4 水平较高的情况下支持 FoxP3+调节性 T 细胞的稳态。
Front Immunol. 2020 Dec 8;11:600000. doi: 10.3389/fimmu.2020.600000. eCollection 2020.
2
Localized Interleukin-12 for Cancer Immunotherapy.局部白介素-12 用于癌症免疫治疗。
Front Immunol. 2020 Oct 15;11:575597. doi: 10.3389/fimmu.2020.575597. eCollection 2020.
3
Molecular mechanisms of dendritic cell migration in immunity and cancer.
Cells. 2025 May 30;14(11):812. doi: 10.3390/cells14110812.
4
Cytokine-overexpressing dendritic cells for cancer immunotherapy.用于癌症免疫治疗的细胞因子过表达树突状细胞
Exp Mol Med. 2024 Dec;56(12):2559-2568. doi: 10.1038/s12276-024-01353-5. Epub 2024 Dec 2.
5
Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy.白细胞介素-12递送策略与肿瘤免疫治疗进展
Curr Issues Mol Biol. 2024 Oct 16;46(10):11548-11579. doi: 10.3390/cimb46100686.
6
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity.嵌合抗原受体（CAR）细胞效应器的谱系：抗肿瘤免疫中的作用模式
Cancers (Basel). 2024 Jul 22;16(14):2608. doi: 10.3390/cancers16142608.
7
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.肿瘤特异性新抗原的 TCR-T 细胞的筛选、鉴定、设计与临床应用。
Mol Cancer. 2023 Aug 30;22(1):141. doi: 10.1186/s12943-023-01844-5.
8
Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines.抗 IL-10R 抗体、HES-MTX 纳米缀合物的多组分化疗免疫疗法抑制 MC38 结肠癌生长依赖于应用分泌 IL-12、IL-15 或 IL-18 的树突状细胞疫苗。
Front Immunol. 2023 Jul 20;14:1212606. doi: 10.3389/fimmu.2023.1212606. eCollection 2023.
9
Combined therapy with methotrexate nanoconjugate and dendritic cells with downregulated IL-10R expression modulates the tumor microenvironment and enhances the systemic anti-tumor immune response in MC38 murine colon carcinoma.甲氨蝶呤纳米偶联物和下调 IL-10R 表达的树突状细胞联合治疗调节 MC38 结肠癌细胞肿瘤微环境并增强全身抗肿瘤免疫反应。
Front Immunol. 2023 Mar 23;14:1155377. doi: 10.3389/fimmu.2023.1155377. eCollection 2023.
10
IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines.白细胞介素 9 将巨噬细胞极化为 M1 型，并通过巨噬细胞炎性蛋白 1 和 CXC 趋化因子受体 3 趋化抗肿瘤免疫细胞浸润。
Cancer Res Commun. 2023 Jan 18;3(1):80-96. doi: 10.1158/2767-9764.CRC-22-0246. eCollection 2023 Jan.
树突状细胞迁移的分子机制在免疫和癌症中的作用。
Med Microbiol Immunol. 2020 Aug;209(4):515-529. doi: 10.1007/s00430-020-00680-4. Epub 2020 May 25.
4
Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.抗癌疫苗接种中的树突状细胞：体外负载或体内靶向的原理
Cancers (Basel). 2020 Mar 5;12(3):590. doi: 10.3390/cancers12030590.
5
Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination.人类浆细胞样树突状细胞（pDCs）在接受树突状细胞（DC）疫苗接种的黑色素瘤患者中比经典型树突状细胞（cDC2s）更能吸引细胞毒性淋巴细胞。
Cell Rep. 2020 Jan 28;30(4):1027-1038.e4. doi: 10.1016/j.celrep.2019.12.096.
6
Dendritic cells in cancer immunology and immunotherapy.树突状细胞在癌症免疫和免疫治疗中的作用。
Nat Rev Immunol. 2020 Jan;20(1):7-24. doi: 10.1038/s41577-019-0210-z. Epub 2019 Aug 29.
7
Lymphatic Migration of Immune Cells.免疫细胞的淋巴迁移。
Front Immunol. 2019 May 28;10:1168. doi: 10.3389/fimmu.2019.01168. eCollection 2019.
8
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention.树突状细胞与癌症：从生物学到治疗干预
Cancers (Basel). 2019 Apr 11;11(4):521. doi: 10.3390/cancers11040521.
9
Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses.将树突状细胞受体用作增强抗癌免疫反应的靶点
Cancers (Basel). 2019 Mar 24;11(3):418. doi: 10.3390/cancers11030418.
10
Between biology and medicine: perspectives on the use of dendritic cells in anticancer therapy.介于生物学与医学之间：关于树突状细胞在抗癌治疗中应用的观点
Postepy Hig Med Dosw (Online). 2017 Nov 19;71(0):921-941. doi: 10.5604/01.3001.0010.5808.